Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Multiple Myeloma 8Prostatic Neoplasms 6Neoplasms, Plasma Cell 6Sarcoma 5Neoplasms 5Melanoma 4Liver Neoplasms 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Hepatocellular 4Lymphoma, Follicular 3Leukemia 3Carcinoma, Renal Cell 3Brain Neoplasms 3Myelodysplastic Syndromes 2Lymphoma 2Kidney Neoplasms 2HIV Infections 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Acquired Immunodeficiency Syndrome 2Waldenstrom Macroglobulinemia 1Urologic Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomatitis, Aphthous 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Endometrial Stromal 1Recurrent Uterine Corpus Sarcoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1

Interventions

Rituximab 33Cyclophosphamide 23Filgrastim 18Peripheral Blood Stem Cell Transplantation 16Etoposide 13fludarabine phosphate 12Vincristine 12Prednisone 11Bortezomib 11sargramostim 10Radiotherapy 10Doxorubicin 8Cytarabine 8Cyclosporine 8Vorinostat 7Lenalidomide 7Cisplatin 7Biopsy 7tanespimycin 6Melphalan 6Magnetic Resonance Spectroscopy 6Ifosfamide 6bryostatin 1 5alvocidib 5aldesleukin 5Specimen Handling 5Methylprednisolone 5Methotrexate 5Interferon-alpha 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Lymphoma, Follicular × Thalidomide × Clear all
NCT00052416 2013-06-26

Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT00015912 2013-01-25

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
35 enrolled
Lymphoid

Lymphoma, Follicular

NCT00022581 2013-01-07

Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
45 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡